Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Modular Medical Inc(MODD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MODD
10/02/2026: MODD (1-star) is currently NOT-A-BUY. Pass it for now.
Modular Medical Inc is an early-stage medical device company focused on developing simplified, cost-effective insulin pump technology to help manage diabetes. Its main strength lies in its user-centric product design, which aims to lower barriers to adoption for patients overwhelmed by complex medical devices. The primary investment story rests on the company’s ability to secure regulatory clearance and successfully launch its MODD1 pump in a large, under-penetrated market. Key risks include intense competition from established industry giants, potential regulatory hurdles, and the need for ongoing capital to reach profitability. The stock may suit growth-oriented investors with high risk tolerance who are looking for exposure to the medical technology sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to the insulin pump market but lacks established commercial momentum. |
| Momentum investor | Weak fit | The stock lacks the consistent uptrend and volume signals typically required for momentum strategies. |
| Value investor | Weak fit | As an early-stage development company, there are no earnings or cash flows to support a traditional value-based valuation. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on reinvesting capital for product development. |
| Low-risk investor | Weak fit | High binary risk related to product commercialization and financing makes this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a small-cap development stage stock, price swings can be extreme based on regulatory news. |
| Valuation risk | High | Without proven revenue, valuation is speculative and highly sensitive to management execution. |
| Competition risk (Market Incumbents) | High | The company faces well-capitalized incumbents like Insulet and Medtronic with deep market penetration. |
| Business quality | Medium | The focus on a simplified user interface is a strong niche, but yet to be tested at scale. |
| Dividend income | Low / none | There is no dividend income to provide a buffer for volatility. |
| Execution risk | High | The company's survival depends on successful FDA approval and effective go-to-market strategies. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -54.24% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.95M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 214.9K shares | Beta 0.24 | 52 Weeks Range 1.72 - 21.15 | Updated Date 10/01/2026 |
52 Weeks Range 1.72 - 21.15 | Updated Date 10/01/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.15 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Insulin Pump Sales | Anticipated sales of the MODD1 insulin pump and associated recurring revenue from disposables. | The company expects to generate revenue primarily through the future sales of its hardware pump devices and ongoing consumable supplies. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14.45M | Price to Sales(TTM) - |
Enterprise Value 14.45M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.21 | Shares Outstanding 8.15M | Shares Floating 7.14M |
Shares Outstanding 8.15M | Shares Floating 7.14M | ||
Percent Insiders 1.69 | Percent Institutions 28.08 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Modular Medical Inc
Exchange NASDAQ | Headquarters San Diego, CA, United States | ||
IPO Launch date 2007-01-25 | CEO - | ||
Sector Healthcare | Industry Medical Devices | Full time employees 51 | Website https://www.modularmedical.com |
Full time employees 51 | Website https://www.modularmedical.com | ||
Modular Medical, Inc. operates as a medical device company. The company focuses on the design, development, and commercialization of insulin pumps. It offers Pivot product, a tubeless insulin delivery system that integrates the set into a true tubeless patch. Modular Medical, Inc. is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.